Adamis Pharmaceuticals Corporation [ADMP] has traded in a range of $0.27 to $1.51 in the last 1 year. As of this writing, the stock is at $0.91, down -3.03%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, ADMP shares are 2.65% up with the monthly amount drift of 12.77% and seems well in a long time frame.

On 18, September 2020, Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock. According to news published on Yahoo Finance, Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today the pricing of its previously announced underwritten public offering of 16,129,032 shares of its common stock at a public offering price of $0.62 per share, resulting in gross proceeds of approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company. All shares of common stock to be sold in the public offering are being sold by Adamis.

Analyst Birdseye View:

The most recent analyst activity for Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] stock was on February 27, 2020, when it was Downgrade with a Neutral rating from Dawson James. Before that, on May 13, 2020, Maxim Group Recapitulated a Buy rating and elevated its amount target to $1.50. On November 26, 2019, Raymond James Downgrade a Mkt perform rating. On July 16, 2019, B. Riley FBR Downgrade a Sell rating and decreased its price target from $1.90 to $1.10. On November 12, 2018, B. Riley FBR Downgrade a Neutral rating and decreased its price target to $2.50. On May 11, 2018, Maxim Group Reiterated a Buy rating and boosted its amount target on this stock to $10. On March 23, 2018, B. Riley FBR Inc. Reiterated a Buy rating and boosted its target amount on this stock from $6.25 to $7.50. Maxim Group elevated its amount target by recapitulating a higher weight for this stock.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.27 and a peak of $1.51. Right now, according to Wall Street analyst the average 12-month amount target is $1.25. At the most recent market close, shares of Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] were valued at $0.91. According to the average price forecast, investors can expect a potential return of 0.0%.


Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] most recently reported quarterly sales of 3.93 billion, which represented growth of -32.80%. This publicly-traded organization’s revenue is $129,321 per employee, while its income is -$171,385 per employee. This company’s Gross Margin is currently 17.30%, its Pretax Margin is -135.44, and its Net Margin is -132.53. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -54.46, -70.85, -67.13 and -69.60 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 10.17 and the whole liability to whole assets at 8.28. It shows enduring liability to the whole principal at 3.69 and enduring liability to assets at 0.03 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.8557 points at 1st support level, the second support level is making up to 0.8004. But as of 1st resistance point, this stock is sitting at 0.9607 and at 1.0104 for 2nd resistance point.

Adamis Pharmaceuticals Corporation [ADMP] reported its earnings at -$0.15 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.08/share signifying the difference of -0.07 and -87.50% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.15 calling estimates for -$0.06/share with the difference of -0.09 depicting the surprise of -150.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] is 1.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.86. Now if looking for a valuation of this stock’s amount to sales ratio it’s 1.69 and it’s amount to book ratio is 1.20.

Insider Stories

The most recent insider trade was by Hopkins Robert O, Chief Financial Officer, and it was the sale of 20000.0 shares on Sep 29. Marguglio David J., the SVP and Chief Business Officer, completed a sale of 20000.0 shares on Sep 29. On Aug 18, Marguglio David J., SVP and Chief Business Officer, completed a sale of 8749.0 shares.